CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinue production of Fluorognost HIV-1 IFA test kits routinely used for confirmation of HIV-1 antibody-reactive donations. Based on our current testing volume, CTS has sufficient HIV-1 IFA reagent inventory to continue performing this confirmatory test through the end of August 2019.
Check out the Communication page for the complete details on the updated IFA HIV-1 assay or by clicking the link: Communications
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...